السوق العالمية للتشخيص الجزيئي للأورام - اتجاهات الصناعة والتوقعات حتى عام 2030

1 INTRODUCTION

1.1 OBJECTIVES OF THE STUDY

1.2 MARKET DEFINITION

1.3 OVERVIEW OF GLOBAL ONCOLOGY MOLECULAR DIAGNOSTIC MARKET

1.4 CURRENCY AND PRICING

1.5 LIMITATION

1.6 MARKETS COVERED

2 MARKET SEGMENTATION

2.1 KEY TAKEAWAYS

2.2 ARRIVING AT THE GLOBAL ONCOLOGY MOLECULAR DIAGNOSTIC MARKETSIZE

2.2.1 VENDOR POSITIONING GRID

2.2.2 TECHNOLOGY LIFE LINE CURVE

2.2.3 TRIPOD DATA VALIDATION MODEL

2.2.4 MARKET GUIDE

2.2.5 MULTIVARIATE MODELLING

2.2.6 TOP TO BOTTOM ANALYSIS

2.2.7 CHALLENGE MATRIX

2.2.8 APPLICATION COVERAGE GRID

2.2.9 STANDARDS OF MEASUREMENT

2.2.10 VENDOR SHARE ANALYSIS

2.2.11 TEST DATA VOLUME

2.2.12 EPIDEMIOLOGY

2.2.13 DATA POINTS FROM KEY PRIMARY INTERVIEWS

2.2.14 DATA POINTS FROM KEY SECONDARY DATABASES

2.3 GLOBAL ONCOLOGY MOLECULAR DIAGNOSTIC MARKET: RESEARCH SNAPSHOT

2.4 ASSUMPTIONS

3 MARKET OVERVIEW

3.1 DRIVERS

3.2 RESTRAINTS

3.3 OPPORTUNITIES

3.4 CHALLENGES

4 EXECUTIVE SUMMARY

5 PREMIUM INSIGHTS

5.1 KEY TRENDS

5.2 PRODUCT INNOVATION & TECHNOLOGY OVERVIEW

5.3 KEY PLAYERS STRATEGIES

5.4 LONG TERM GROWTH APPROACH

5.5 OTHERS

6 EPIDEMIOLOGY

6.1 INCIDENCE OF ALL BY GENDER

6.2 DIAGNOSIS RATE

6.3 MORTALITY RATE

6.4 PATEINT TREATMENT SUCCESS RATES

7 INDUSTRY INSIGHTS

7.1 PATENT ANALYSIS

7.2 ONCOLOGY MOLECULAR DIAGNOSTIC RATE BY MATURED MARKETS

7.3 DEMOGRAPHIC TRENDS: IMPACTS ON ALL INCIDENCE RATES

7.4 PATIENT FLOW DIAGRAM

7.5 KEY PRICING STRATEGIES

7.6 KEY PATIENT ENROLLMENT STRATEGIES

7.7 INTERVIEWS WITH VIROLOGIST

7.8 OTHER KOL SNAPSHOTS

8 GLOBAL ONCOLOGY MOLECULAR DIAGNOSTIC MARKET, BY PRODUCT

8.1 OVERVIEW

8.2 KITS & REAGENTS

8.2.1 MUTATIONS DETECTION KIT

8.2.1.1. MARKET VALUE (USD MILLION)

8.2.1.2. MARKET VOLUME (UNITS)

8.2.1.3. AVERAGE SELLING PRICE (USD)

8.2.2 PANEL KIT

8.2.2.1. MARKET VALUE (USD MILLION)

8.2.2.2. MARKET VOLUME (UNITS)

8.2.2.3. AVERAGE SELLING PRICE (USD)

8.2.3 MPN PANEL KIT

8.2.3.1. MARKET VALUE (USD MILLION)

8.2.3.2. MARKET VOLUME (UNITS)

8.2.3.3. AVERAGE SELLING PRICE (USD)

8.2.4 AML PANEL KIT

8.2.4.1. MARKET VALUE (USD MILLION)

8.2.4.2. MARKET VOLUME (UNITS)

8.2.4.3. AVERAGE SELLING PRICE (USD)

8.2.5 KRAS PCR KIT

8.2.5.1. MARKET VALUE (USD MILLION)

8.2.5.2. MARKET VOLUME (UNITS)

8.2.5.3. AVERAGE SELLING PRICE (USD)

8.2.6 EGFR KIT

8.2.6.1. MARKET VALUE (USD MILLION)

8.2.6.2. MARKET VOLUME (UNITS)

8.2.6.3. AVERAGE SELLING PRICE (USD)

8.2.7 BRAF MUTATION KIT

8.2.7.1. MARKET VALUE (USD MILLION)

8.2.7.2. MARKET VOLUME (UNITS)

8.2.7.3. AVERAGE SELLING PRICE (USD)

8.2.8 ALL PANEL KIT

8.2.8.1. MARKET VALUE (USD MILLION)

8.2.8.2. MARKET VOLUME (UNITS)

8.2.8.3. AVERAGE SELLING PRICE (USD)

8.2.9 AML1-ETO KIT

8.2.9.1. MARKET VALUE (USD MILLION)

8.2.9.2. MARKET VOLUME (UNITS)

8.2.9.3. AVERAGE SELLING PRICE (USD)

8.2.10 NRAS MUTATION KIT

8.2.10.1. MARKET VALUE (USD MILLION)

8.2.10.2. MARKET VOLUME (UNITS)

8.2.10.3. AVERAGE SELLING PRICE (USD)

8.2.11 CALR KIT

8.2.11.1. MARKET VALUE (USD MILLION)

8.2.11.2. MARKET VOLUME (UNITS)

8.2.11.3. AVERAGE SELLING PRICE (USD)

8.2.12 FLT3 MUTATION DETECTION

8.2.12.1. MARKET VALUE (USD MILLION)

8.2.12.2. MARKET VOLUME (UNITS)

8.2.12.3. AVERAGE SELLING PRICE (USD)

8.2.13 C-KIT MUTATION DETECTION KIT

8.2.13.1. MARKET VALUE (USD MILLION)

8.2.13.2. MARKET VOLUME (UNITS)

8.2.13.3. AVERAGE SELLING PRICE (USD)

8.2.14 MGMT METHYLATION DETECTION KIT

8.2.14.1. MARKET VALUE (USD MILLION)

8.2.14.2. MARKET VOLUME (UNITS)

8.2.14.3. AVERAGE SELLING PRICE (USD)

8.2.15 CBFB-MYH11 KIT

8.2.15.1. MARKET VALUE (USD MILLION)

8.2.15.2. MARKET VOLUME (UNITS)

8.2.15.3. AVERAGE SELLING PRICE (USD)

8.2.16 GENE FUSIONS DETECTION KIT

8.2.16.1. MARKET VALUE (USD MILLION)

8.2.16.2. MARKET VOLUME (UNITS)

8.2.16.3. AVERAGE SELLING PRICE (USD)

8.2.17 OTHER

8.3 INSTRUMENTS

8.3.1 BY TYPE

8.3.1.1. PCR SYSTEM

8.3.1.1.1. MARKET VALUE (USD MILLION)

8.3.1.1.2. MARKET VOLUME (UNITS)

8.3.1.1.3. AVERAGE SELLING PRICE (USD)

8.3.1.2. ANALYZER

8.3.1.2.1. MARKET VALUE (USD MILLION)

8.3.1.2.2. MARKET VOLUME (UNITS)

8.3.1.2.3. AVERAGE SELLING PRICE (USD)

8.3.1.3. MICROARRAY SCANNER

8.3.1.3.1. MARKET VALUE (USD MILLION)

8.3.1.3.2. MARKET VOLUME (UNITS)

8.3.1.3.3. AVERAGE SELLING PRICE (USD)

8.3.1.4. GENETIC ANALYSIS SYSTEM

8.3.1.4.1. MARKET VALUE (USD MILLION)

8.3.1.4.2. MARKET VOLUME (UNITS)

8.3.1.4.3. AVERAGE SELLING PRICE (USD)

8.3.1.5. MASS SPECTROMETER

8.3.1.5.1. MARKET VALUE (USD MILLION)

8.3.1.5.2. MARKET VOLUME (UNITS)

8.3.1.5.3. AVERAGE SELLING PRICE (USD)

8.3.1.6. THERMOSHAKERS

8.3.1.6.1. MARKET VALUE (USD MILLION)

8.3.1.6.2. MARKET VOLUME (UNITS)

8.3.1.6.3. AVERAGE SELLING PRICE (USD)

8.3.1.7. HIGH THROUGHPUT SYSTEMS

8.3.1.7.1. MARKET VALUE (USD MILLION)

8.3.1.7.2. MARKET VOLUME (UNITS)

8.3.1.7.3. AVERAGE SELLING PRICE (USD)

8.3.1.8. THERMAL CYCLER

8.3.1.8.1. MARKET VALUE (USD MILLION)

8.3.1.8.2. MARKET VOLUME (UNITS)

8.3.1.8.3. AVERAGE SELLING PRICE (USD)

8.3.1.9. POINT OF CARE DEVICES

8.3.1.9.1. MARKET VALUE (USD MILLION)

8.3.1.9.2. MARKET VOLUME (UNITS)

8.3.1.9.3. AVERAGE SELLING PRICE (USD)

8.3.1.10. PLATFORM/SYSTEM

8.3.1.10.1. MARKET VALUE (USD MILLION)

8.3.1.10.2. MARKET VOLUME (UNITS)

8.3.1.10.3. AVERAGE SELLING PRICE (USD)

8.3.1.11. OTHERS

8.3.2 BY MODALITY

8.3.2.1. STANDALONE

8.3.2.2. PORTABLE

8.3.2.3. BENCHTOP

8.3.3 BY USABILITY

8.3.3.1. FULLY AUTOMATED INSTRUMENTS

8.3.3.2. SEMI-AUTOMATED INSTRUMENTS

9 GLOBAL ONCOLOGY MOLECULAR DIAGNOSTIC MARKET, BY TECHNOLOGY

9.1 OVERVIEW

9.2 POLYMERASE CHAIN REACTION (PCR)-BASED METHODS

9.2.1 REAL-TIME PCR

9.2.2 DIGITAL PCR

9.2.3 REVERSE TRANSCRIPTASE PCR

9.2.4 QUANTITATIVE FLUORESCENT PCR

9.2.5 OTHER

9.3 ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGY (INAAT)

9.4 TRANSCRIPTION MEDIATED AMPLIFICATION (TMA)

9.5 SEQUENCING

9.5.1 NEXT GENERATION SEQUENCING (NGS)

9.5.2 FIRST GENERATION SEQUENCING

9.5.3 SECOND GENERATION SEQUENCING

9.5.4 THIRD GENERATION SEQUENCING

9.6 MASS SPECTROMETRY (MS)

9.7 CHIPS AND MICROARRAY

9.8 CAPILLARY ELECTROPHORESIS

9.9 IN SITU HYBRIDIZATION (ISH OR FISH)

9.1 OTHERS

10 GLOBAL ONCOLOGY MOLECULAR DIAGNOSTIC MARKET, BY CANCER TYPE

10.1 OVERVIEW

10.2 BREAST CANCER

10.2.1 BY PRODUCT

10.2.1.1. KITS & REAGENTS

10.2.1.2. INSTRUMENTS

10.2.2 BY MODE

10.2.2.1. LABORATORY/ CLINICS AND OTHER ESTABLISHMENTS

10.2.2.2. POINT-OF-CARE

10.2.3 BY TECHNOLOGY

10.2.3.1. POLYMERASE CHAIN REACTION (PCR)-BASED METHODS

10.2.3.2. ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGY (INAAT)

10.2.3.3. TRANSCRIPTION MEDIATED AMPLIFICATION (TMA)

10.2.3.4. SEQUENCING

10.2.3.5. MASS SPECTROMETRY (MS)

10.2.3.6. CHIPS AND MICROARRAY

10.2.3.7. CAPILLARY ELECTROPHORESIS

10.2.3.8. IN SITU HYBRIDIZATION (ISH OR FISH)

10.2.3.9. OTHERS

10.3 PROSTATE CANCER

10.3.1 BY PRODUCT

10.3.1.1. KITS & REAGENTS

10.3.1.2. INSTRUMENTS

10.3.2 BY MODE

10.3.2.1. LABORATORY/ CLINICS AND OTHER ESTABLISHMENTS

10.3.2.2. POINT-OF-CARE

10.3.3 BY TECHNOLOGY

10.3.3.1. POLYMERASE CHAIN REACTION (PCR)-BASED METHODS

10.3.3.2. ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGY (INAAT)

10.3.3.3. TRANSCRIPTION MEDIATED AMPLIFICATION (TMA)

10.3.3.4. SEQUENCING

10.3.3.5. MASS SPECTROMETRY (MS)

10.3.3.6. CHIPS AND MICROARRAY

10.3.3.7. CAPILLARY ELECTROPHORESIS

10.3.3.8. IN SITU HYBRIDIZATION (ISH OR FISH)

10.3.3.9. OTHERS

10.4 COLORECTAL CANCER

10.4.1 BY PRODUCT

10.4.1.1. KITS & REAGENTS

10.4.1.2. INSTRUMENTS

10.4.2 BY MODE

10.4.2.1. LABORATORY/ CLINICS AND OTHER ESTABLISHMENTS

10.4.2.2. POINT-OF-CARE

10.4.3 BY TECHNOLOGY

10.4.3.1. POLYMERASE CHAIN REACTION (PCR)-BASED METHODS

10.4.3.2. ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGY (INAAT)

10.4.3.3. TRANSCRIPTION MEDIATED AMPLIFICATION (TMA)

10.4.3.4. SEQUENCING

10.4.3.5. MASS SPECTROMETRY (MS)

10.4.3.6. CHIPS AND MICROARRAY

10.4.3.7. CAPILLARY ELECTROPHORESIS

10.4.3.8. IN SITU HYBRIDIZATION (ISH OR FISH)

10.4.3.9. OTHERS

10.5 CERVICAL CANCER

10.5.1 BY PRODUCT

10.5.1.1. KITS & REAGENTS

10.5.1.2. INSTRUMENTS

10.5.2 BY MODE

10.5.2.1. LABORATORY/ CLINICS AND OTHER ESTABLISHMENTS

10.5.2.2. POINT-OF-CARE

10.5.3 BY TECHNOLOGY

10.5.3.1. POLYMERASE CHAIN REACTION (PCR)-BASED METHODS

10.5.3.2. ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGY (INAAT)

10.5.3.3. TRANSCRIPTION MEDIATED AMPLIFICATION (TMA)

10.5.3.4. SEQUENCING

10.5.3.5. MASS SPECTROMETRY (MS)

10.5.3.6. CHIPS AND MICROARRAY

10.5.3.7. CAPILLARY ELECTROPHORESIS

10.5.3.8. IN SITU HYBRIDIZATION (ISH OR FISH)

10.5.3.9. OTHERS

10.6 LIVER CANCER

10.6.1 BY PRODUCT

10.6.1.1. KITS & REAGENTS

10.6.1.2. INSTRUMENTS

10.6.2 BY MODE

10.6.2.1. LABORATORY/ CLINICS AND OTHER ESTABLISHMENTS

10.6.2.2. POINT-OF-CARE

10.6.3 BY TECHNOLOGY

10.6.3.1. POLYMERASE CHAIN REACTION (PCR)-BASED METHODS

10.6.3.2. ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGY (INAAT)

10.6.3.3. TRANSCRIPTION MEDIATED AMPLIFICATION (TMA)

10.6.3.4. SEQUENCING

10.6.3.5. MASS SPECTROMETRY (MS)

10.6.3.6. CHIPS AND MICROARRAY

10.6.3.7. CAPILLARY ELECTROPHORESIS

10.6.3.8. IN SITU HYBRIDIZATION (ISH OR FISH)

10.6.3.9. OTHERS

10.7 LUNG CANCER

10.7.1 BY PRODUCT

10.7.1.1. KITS & REAGENTS

10.7.1.2. INSTRUMENTS

10.7.2 BY MODE

10.7.2.1. LABORATORY/ CLINICS AND OTHER ESTABLISHMENTS

10.7.2.2. POINT-OF-CARE

10.7.3 BY TECHNOLOGY

10.7.3.1. POLYMERASE CHAIN REACTION (PCR)-BASED METHODS

10.7.3.2. ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGY (INAAT)

10.7.3.3. TRANSCRIPTION MEDIATED AMPLIFICATION (TMA)

10.7.3.4. SEQUENCING

10.7.3.5. MASS SPECTROMETRY (MS)

10.7.3.6. CHIPS AND MICROARRAY

10.7.3.7. CAPILLARY ELECTROPHORESIS

10.7.3.8. IN SITU HYBRIDIZATION (ISH OR FISH)

10.7.3.9. OTHERS

10.8 BLOOD CANCER

10.8.1 BY PRODUCT

10.8.1.1. KITS & REAGENTS

10.8.1.2. INSTRUMENTS

10.8.2 BY MODE

10.8.2.1. LABORATORY/ CLINICS AND OTHER ESTABLISHMENTS

10.8.2.2. POINT-OF-CARE

10.8.3 BY TECHNOLOGY

10.8.3.1. POLYMERASE CHAIN REACTION (PCR)-BASED METHODS

10.8.3.2. ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGY (INAAT)

10.8.3.3. TRANSCRIPTION MEDIATED AMPLIFICATION (TMA)

10.8.3.4. SEQUENCING

10.8.3.5. MASS SPECTROMETRY (MS)

10.8.3.6. CHIPS AND MICROARRAY

10.8.3.7. CAPILLARY ELECTROPHORESIS

10.8.3.8. IN SITU HYBRIDIZATION (ISH OR FISH)

10.8.3.9. OTHERS

10.9 KIDNEY CANCER

10.9.1 BY PRODUCT

10.9.1.1. KITS & REAGENTS

10.9.1.2. INSTRUMENTS

10.9.2 BY MODE

10.9.2.1. LABORATORY/ CLINICS AND OTHER ESTABLISHMENTS

10.9.2.2. POINT-OF-CARE

10.9.3 BY TECHNOLOGY

10.9.3.1. POLYMERASE CHAIN REACTION (PCR)-BASED METHODS

10.9.3.2. ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGY (INAAT)

10.9.3.3. TRANSCRIPTION MEDIATED AMPLIFICATION (TMA)

10.9.3.4. SEQUENCING

10.9.3.5. MASS SPECTROMETRY (MS)

10.9.3.6. CHIPS AND MICROARRAY

10.9.3.7. CAPILLARY ELECTROPHORESIS

10.9.3.8. IN SITU HYBRIDIZATION (ISH OR FISH)

10.9.3.9. OTHERS

10.1 MELANOMA

10.10.1 BY PRODUCT

10.10.1.1. KITS & REAGENTS

10.10.1.2. INSTRUMENTS

10.10.2 BY MODE

10.10.2.1. LABORATORY/ CLINICS AND OTHER ESTABLISHMENTS

10.10.2.2. POINT-OF-CARE

10.10.3 BY TECHNOLOGY

10.10.3.1. POLYMERASE CHAIN REACTION (PCR)-BASED METHODS

10.10.3.2. ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGY (INAAT)

10.10.3.3. TRANSCRIPTION MEDIATED AMPLIFICATION (TMA)

10.10.3.4. SEQUENCING

10.10.3.5. MASS SPECTROMETRY (MS)

10.10.3.6. CHIPS AND MICROARRAY

10.10.3.7. CAPILLARY ELECTROPHORESIS

10.10.3.8. IN SITU HYBRIDIZATION (ISH OR FISH)

10.10.3.9. OTHERS

10.11 OTHERS

11 GLOBAL ONCOLOGY MOLECULAR DIAGNOSTIC MARKET, BY MODE

11.1 OVERVIEW

11.2 LABORATORY/ CLINICS AND OTHER ESTABLISHMENTS

11.2.1 KITS & REAGENTS

11.2.2 INSTRUMENTS

11.3 POINT-OF-CARE

11.3.1 KITS & REAGENTS

11.3.2 INSTRUMENTS

12 GLOBAL ONCOLOGY MOLECULAR DIAGNOSTIC MARKET, BY END USER

12.1 OVERVIEW

12.2 HOSPITALS

12.2.1 BY TYPE

12.2.1.1. TIER 1

12.2.1.2. TIER 2

12.2.1.3. TIER 3

12.2.2 BY PRODUCT

12.2.2.1. KITS & REAGENTS

12.2.2.2. INSTRUMENTS

12.3 SPECIALITY CLINICS

12.3.1 KITS & REAGENTS

12.3.2 INSTRUMENTS

12.4 DIAGNOSTIC LABORATORIES

12.4.1 KITS & REAGENTS

12.4.2 INSTRUMENTS

12.5 CANCER RESEARCH INSTITUTES BY PRODUCT

12.5.1 KITS & REAGENTS

12.5.2 INSTRUMENTS

12.6 ACADEMIC AND RESEARCH INSTITUTES

12.6.1 KITS & REAGENTS

12.6.2 INSTRUMENTS

12.7 OTHERS

13 GLOBAL ONCOLOGY MOLECULAR DIAGNOSTIC MARKET, BY DISTRIBUTION CHANNEL

13.1 OVERVIEW

13.2 DIRECT TENDERS

13.3 RETAIL SALES

13.4 ONLINE SALES

13.5 OTHERS

14 GLOBAL ONCOLOGY MOLECULAR DIAGNOSTIC MARKET, COMPANY LANDSCAPE

14.1 COMPANY SHARE ANALYSIS: GLOBAL

14.2 COMPANY SHARE ANALYSIS: NORTH AMERICA

14.3 COMPANY SHARE ANALYSIS: EUROPE

14.4 COMPANY SHARE ANALYSIS: ASIA-PACIFIC

14.5 MERGERS & ACQUISITIONS

14.6 NEW PRODUCT DEVELOPMENT & APPROVALS

14.7 EXPANSIONS

14.8 REGULATORY CHANGES

14.9 PARTNERSHIP AND OTHER STRATEGIC DEVELOPMENTS

14.1 MARKET ATTRACTIVENESS

15 GLOBAL ONCOLOGY MOLECULAR DIAGNOSTIC MARKET, BY REGION

GLOBAL ONCOLOGY MOLECULAR DIAGNOSTIC MARKET (ALL SEGMENTATION PROVIDED ABOVE IS REPRESENTED IN THIS CHAPTER BY COUNTRY)

15.1 NORTH AMERICA

15.1.1 U.S.

15.1.2 CANADA

15.1.3 MEXICO

15.2 EUROPE

15.2.1 GERMANY

15.2.2 U.K.

15.2.3 ITALY

15.2.4 FRANCE

15.2.5 SPAIN

15.2.6 RUSSIA

15.2.7 SWITZERLAND

15.2.8 TURKEY

15.2.9 BELGIUM

15.2.10 NETHERLANDS

15.2.11 DENMARK

15.2.12 SWEDEN

15.2.13 POLAND

15.2.14 NORWAY

15.2.15 FINLAND

15.2.16 REST OF EUROPE

15.3 ASIA-PACIFIC

15.3.1 JAPAN

15.3.2 CHINA

15.3.3 SOUTH KOREA

15.3.4 INDIA

15.3.5 SINGAPORE

15.3.6 THAILAND

15.3.7 INDONESIA

15.3.8 MALAYSIA

15.3.9 PHILIPPINES

15.3.10 AUSTRALIA

15.3.11 NEW ZEALAND

15.3.12 VIETNAM

15.3.13 TAIWAN

15.3.14 REST OF ASIA-PACIFIC

15.4 LATIN AMERICA

15.4.1 BRAZIL

15.4.2 ARGENTINA

15.4.3 REST OF LATIN AMERICA

15.5 MIDDLE EAST AND AFRICA

15.5.1 SOUTH AFRICA

15.5.2 EGYPT

15.5.3 BAHRAIN

15.5.4 UNITED ARAB EMIRATES

15.5.5 KUWAIT

15.5.6 OMAN

15.5.7 QATAR

15.5.8 SAUDI ARABIA

15.5.9 REST OF MEA

15.6 KEY PRIMARY INSIGHTS: BY MAJOR COUNTRIES

16 GLOBAL ONCOLOGY MOLECULAR DIAGNOSTIC MARKET, SWOT ANALYSIS

17 GLOBAL ONCOLOGY MOLECULAR DIAGNOSTIC MARKET, COMPANY PROFILE

17.1 ABBOTT LABORATORIES

17.1.1 COMPANY OVERVIEW

17.1.2 REVENUE ANALYSIS

17.1.3 GEOGRAPHIC PRESENCE

17.1.4 PRODUCT PORTFOLIO

17.1.5 RECENT DEVELOPEMENTS

17.2 F. HOFFMANN-LA ROCHE LTD

17.2.1 COMPANY OVERVIEW

17.2.2 REVENUE ANALYSIS

17.2.3 GEOGRAPHIC PRESENCE

17.2.4 PRODUCT PORTFOLIO

17.2.5 RECENT DEVELOPEMENTS

17.3 ILLUMINA, INC.

17.3.1 COMPANY OVERVIEW

17.3.2 REVENUE ANALYSIS

17.3.3 GEOGRAPHIC PRESENCE

17.3.4 PRODUCT PORTFOLIO

17.3.5 RECENT DEVELOPEMENTS

17.4 HOLOGIC, INC.

17.4.1 COMPANY OVERVIEW

17.4.2 REVENUE ANALYSIS

17.4.3 GEOGRAPHIC PRESENCE

17.4.4 PRODUCT PORTFOLIO

17.4.5 RECENT DEVELOPEMENTS

17.5 BIOMÉRIEUX

17.5.1 COMPANY OVERVIEW

17.5.2 REVENUE ANALYSIS

17.5.3 GEOGRAPHIC PRESENCE

17.5.4 PRODUCT PORTFOLIO

17.5.5 RECENT DEVELOPEMENTS

17.6 AGILENT TECHNOLOGIES, INC

17.6.1 COMPANY OVERVIEW

17.6.2 REVENUE ANALYSIS

17.6.3 GEOGRAPHIC PRESENCE

17.6.4 PRODUCT PORTFOLIO

17.6.5 RECENT DEVELOPEMENTS

17.7 BD

17.7.1 COMPANY OVERVIEW

17.7.2 REVENUE ANALYSIS

17.7.3 GEOGRAPHIC PRESENCE

17.7.4 PRODUCT PORTFOLIO

17.7.5 RECENT DEVELOPEMENTS

17.8 BECKMAN COULTER, INC.

17.8.1 COMPANY OVERVIEW

17.8.2 REVENUE ANALYSIS

17.8.3 GEOGRAPHIC PRESENCE

17.8.4 PRODUCT PORTFOLIO

17.8.5 RECENT DEVELOPEMENTS

17.9 THERMO FISHER SCIENTIFIC INC.

17.9.1 COMPANY OVERVIEW

17.9.2 REVENUE ANALYSIS

17.9.3 GEOGRAPHIC PRESENCE

17.9.4 PRODUCT PORTFOLIO

17.9.5 RECENT DEVELOPEMENTS

17.1 BIODESIX

17.10.1 COMPANY OVERVIEW

17.10.2 REVENUE ANALYSIS

17.10.3 GEOGRAPHIC PRESENCE

17.10.4 PRODUCT PORTFOLIO

17.10.5 RECENT DEVELOPEMENTS

17.11 INTEGRATED DNA TECHNOLOGIES, INC.

17.11.1 COMPANY OVERVIEW

17.11.2 REVENUE ANALYSIS

17.11.3 GEOGRAPHIC PRESENCE

17.11.4 PRODUCT PORTFOLIO

17.11.5 RECENT DEVELOPEMENTS

17.12 BIONTECH SE.

17.12.1 COMPANY OVERVIEW

17.12.2 REVENUE ANALYSIS

17.12.3 GEOGRAPHIC PRESENCE

17.12.4 PRODUCT PORTFOLIO

17.12.5 RECENT DEVELOPEMENTS

17.13 SIEMENS HEALTHCARE GMBH

17.13.1 COMPANY OVERVIEW

17.13.2 REVENUE ANALYSIS

17.13.3 GEOGRAPHIC PRESENCE

17.13.4 PRODUCT PORTFOLIO

17.13.5 RECENT DEVELOPEMENTS

17.14 BAYER AG

17.14.1 COMPANY OVERVIEW

17.14.2 REVENUE ANALYSIS

17.14.3 GEOGRAPHIC PRESENCE

17.14.4 PRODUCT PORTFOLIO

17.14.5 RECENT DEVELOPEMENTS

17.15 SYSMEX SE,

17.15.1 COMPANY OVERVIEW

17.15.2 REVENUE ANALYSIS

17.15.3 GEOGRAPHIC PRESENCE

17.15.4 PRODUCT PORTFOLIO

17.15.5 RECENT DEVELOPEMENTS

17.16 DANAHER

17.16.1 COMPANY OVERVIEW

17.16.2 REVENUE ANALYSIS

17.16.3 GEOGRAPHIC PRESENCE

17.16.4 PRODUCT PORTFOLIO

17.16.5 RECENT DEVELOPEMENTS

17.17 QIAGEN

17.17.1 COMPANY OVERVIEW

17.17.2 REVENUE ANALYSIS

17.17.3 GEOGRAPHIC PRESENCE

17.17.4 PRODUCT PORTFOLIO

17.17.5 RECENT DEVELOPEMENTS

17.18 CEPHEID

17.18.1 COMPANY OVERVIEW

17.18.2 REVENUE ANALYSIS

17.18.3 GEOGRAPHIC PRESENCE

17.18.4 PRODUCT PORTFOLIO

17.18.5 RECENT DEVELOPEMENTS

17.19 VERACYTE, INC

17.19.1 COMPANY OVERVIEW

17.19.2 REVENUE ANALYSIS

17.19.3 GEOGRAPHIC PRESENCE

17.19.4 PRODUCT PORTFOLIO

17.19.5 RECENT DEVELOPEMENTS

17.2 DIASORIN MOLECULAR LLC

17.20.1 COMPANY OVERVIEW

17.20.2 REVENUE ANALYSIS

17.20.3 GEOGRAPHIC PRESENCE

17.20.4 PRODUCT PORTFOLIO

17.20.5 RECENT DEVELOPEMENTS

17.21 GRIFOLS, S.A.

17.21.1 COMPANY OVERVIEW

17.21.2 REVENUE ANALYSIS

17.21.3 GEOGRAPHIC PRESENCE

17.21.4 PRODUCT PORTFOLIO

17.21.5 RECENT DEVELOPEMENTS

17.22 LEICA BIOSYSTEMS NUSSLOCH GMBH (DANAHER CORPORATION)

17.22.1 COMPANY OVERVIEW

17.22.2 REVENUE ANALYSIS

17.22.3 GEOGRAPHIC PRESENCE

17.22.4 PRODUCT PORTFOLIO

17.22.5 RECENT DEVELOPEMENTS

17.23 ANALYTIK JENA GMBH

17.23.1 COMPANY OVERVIEW

17.23.2 REVENUE ANALYSIS

17.23.3 GEOGRAPHIC PRESENCE

17.23.4 PRODUCT PORTFOLIO

17.23.5 RECENT DEVELOPEMENTS

17.24 BIOCARTIS

17.24.1 COMPANY OVERVIEW

17.24.2 REVENUE ANALYSIS

17.24.3 GEOGRAPHIC PRESENCE

17.24.4 PRODUCT PORTFOLIO

17.24.5 RECENT DEVELOPEMENTS

17.25 LUMINEX CORPORATION

17.25.1 COMPANY OVERVIEW

17.25.2 REVENUE ANALYSIS

17.25.3 GEOGRAPHIC PRESENCE

17.25.4 PRODUCT PORTFOLIO

17.25.5 RECENT DEVELOPEMENTS

18 RELATED REPORTS

19 CONCLUSION

20 QUESTIONNAIRE

21 ABOUT DATA BRIDGE MARKET RESEARCH